![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAGEC2 |
Gene summary for MAGEC2 |
![]() |
Gene information | Species | Human | Gene symbol | MAGEC2 | Gene ID | 51438 |
Gene name | MAGE family member C2 | |
Gene Alias | CT10 | |
Cytomap | Xq27.2 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9UBF1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51438 | MAGEC2 | S014 | Human | Liver | HCC | 1.72e-35 | 1.39e+00 | 0.2254 |
51438 | MAGEC2 | S015 | Human | Liver | HCC | 7.02e-42 | 1.71e+00 | 0.2375 |
51438 | MAGEC2 | S016 | Human | Liver | HCC | 3.86e-45 | 1.49e+00 | 0.2243 |
51438 | MAGEC2 | S028 | Human | Liver | HCC | 3.51e-22 | 6.86e-01 | 0.2503 |
51438 | MAGEC2 | S029 | Human | Liver | HCC | 7.94e-23 | 7.21e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332022 | Liver | HCC | regulation of protein modification by small protein conjugation or removal | 167/7958 | 242/18723 | 4.99e-17 | 4.72e-15 | 167 |
GO:003139622 | Liver | HCC | regulation of protein ubiquitination | 142/7958 | 210/18723 | 1.39e-13 | 7.81e-12 | 142 |
GO:19033221 | Liver | HCC | positive regulation of protein modification by small protein conjugation or removal | 94/7958 | 138/18723 | 9.87e-10 | 3.01e-08 | 94 |
GO:00313981 | Liver | HCC | positive regulation of protein ubiquitination | 79/7958 | 119/18723 | 1.18e-07 | 2.26e-06 | 79 |
GO:005143821 | Liver | HCC | regulation of ubiquitin-protein transferase activity | 36/7958 | 53/18723 | 1.62e-04 | 1.29e-03 | 36 |
GO:0051443 | Liver | HCC | positive regulation of ubiquitin-protein transferase activity | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGEC2 | SNV | Missense_Mutation | c.1054N>A | p.Asp352Asn | p.D352N | Q9UBF1 | protein_coding | tolerated(0.13) | benign(0.168) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MAGEC2 | SNV | Missense_Mutation | novel | c.868N>G | p.Pro290Ala | p.P290A | Q9UBF1 | protein_coding | deleterious(0.04) | possibly_damaging(0.816) | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
MAGEC2 | SNV | Missense_Mutation | c.494N>T | p.Ala165Val | p.A165V | Q9UBF1 | protein_coding | tolerated(0.05) | possibly_damaging(0.77) | TCGA-B6-A0X5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
MAGEC2 | SNV | Missense_Mutation | c.218N>G | p.Ser73Cys | p.S73C | Q9UBF1 | protein_coding | deleterious(0.01) | possibly_damaging(0.657) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAGEC2 | SNV | Missense_Mutation | c.34N>A | p.Val12Ile | p.V12I | Q9UBF1 | protein_coding | tolerated_low_confidence(0.42) | benign(0.007) | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD | |
MAGEC2 | SNV | Missense_Mutation | c.741N>C | p.Glu247Asp | p.E247D | Q9UBF1 | protein_coding | deleterious(0.03) | possibly_damaging(0.857) | TCGA-EW-A1P8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD | |
MAGEC2 | SNV | Missense_Mutation | rs760988978 | c.1043T>C | p.Ile348Thr | p.I348T | Q9UBF1 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
MAGEC2 | insertion | Nonsense_Mutation | novel | c.104_105insCATGTAATCCTAGGGTAAGAGAGTTTTTGAGATCATC | p.Glu35AspfsTer3 | p.E35Dfs*3 | Q9UBF1 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
MAGEC2 | SNV | Missense_Mutation | c.1061N>T | p.Ala354Val | p.A354V | Q9UBF1 | protein_coding | deleterious(0.01) | benign(0.103) | TCGA-BI-A20A-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGEC2 | SNV | Missense_Mutation | rs142943547 | c.860G>A | p.Arg287Gln | p.R287Q | Q9UBF1 | protein_coding | tolerated(0.2) | benign(0.196) | TCGA-RA-A741-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
51438 | MAGEC2 | ENZYME | CV-9201 |
Page: 1 |